Array BioPharma (ARRY) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($1.8 million) and the uptick to downtick ratio was 0.87. The transaction value on upticks was $12.56 million and on downticks, the transaction value was $14.36 million. In block trades, the transaction value of inflow done during uptick was $1.23 million. The transaction value of block trades during downticks was $2.39 million. The uptick to downtick block trade ratio was 0.51. The money flow was negative ($1.16 million), indicating the traders were booking profit on the price strength. Array BioPharma (ARRY) rose $0.02 at $6.61, during intraday Wednesday , a rise of 0.3% over the previous days close.
Shares of Array BioPharma Inc. rose by 74.93% in the last five trading days and 82.56% for the last 4 weeks. Array BioPharma Inc. is up 79.94% in the last 3-month period. Year-to-Date the stock performance stands at 48.82%.
Array BioPharma (ARRY) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Array BioPharma (NASDAQ:ARRY): stock was range-bound between the intraday low of $6.18 and the intraday high of $6.95 after having opened at $6.52 on Wednesdays session. The stock finally closed in the red at $6.52, a loss of -4.70%. The stock remained in the red for the whole trading day. The total traded volume was 29,967,153 shares. The stock failed to cross $6.95 in Wednesdays trading. The stocks closing price on Thursday was $6.59.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.